Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion InfusionsDHA:ORIONINFU -0.66%80 5-Year Yield-on-Cost % is 0.69 as of Jul. 30, 2026, which is 47% below its 10-year median of 1.31. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 80/100 and a GF Value™ of BDT315.25 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 513 Drug Manufacturers companies, Orion Infusions ranks worse than 77.39% on this metric.
Orion Infusions's yield on cost for the quarter that ended in Mar. 2026 was 0.69.
The historical rank and industry rank for Orion Infusions's 5-Year Yield-on-Cost % or its related term are showing as below:
DHA:ORIONINFU'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.1 Med: 1.31 Max: 3.03
Current: 0.69
During the past 13 years, Orion Infusions's highest Yield on Cost was 3.03. The lowest was 0.10. And the median was 1.31.
DHA:ORIONINFU's 5-Year Yield-on-Cost % is ranked worse than 77.39% of 513
companies
in the Drug Manufacturers industry
Industry Median: 2.29
vs DHA:ORIONINFU: 0.69
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Orion Infusions 5-Year Yield-on-Cost % Related Terms
DHA:ORIONINFU vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Infusions 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Orion Infusions's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Orion Infusions is calculated as
Orion Infusions (DHA:ORIONINFU) has a 5-Year Yield-on-Cost % of 0.69 as of Jul. 30, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Orion Infusions and its competitors. This is 47% below median its historical median of 1.31. Over the past decade, Orion Infusions' 5-Year Yield-on-Cost % has ranged from 0.10 to 3.03. According to the industry distribution chart, Orion Infusions ranks #397 out of 513 companies in the Drug Manufacturers industry, placing it in the top 77.4%.
Is Orion Infusions' 5-Year Yield-on-Cost % too high?
Orion Infusions' current 5-Year Yield-on-Cost % of 0.69 is 47% below median its 10-year median of 1.31. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 3.03. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.29. Orion Infusions' value of 0.69 is 69.9% below this industry median. Based on the distribution chart, Orion Infusions ranks #397 out of 513 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Orion Infusions has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orion Infusions ranks #397 out of 513 companies for 5-Year Yield-on-Cost %. This places Orion Infusions in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.29. Orion Infusions' value of 0.69 is 69.9% below this benchmark. Historically, Orion Infusions' own 5-Year Yield-on-Cost % has ranged from 0.10 to 3.03 over the past decade. While the company's 10-year median is 1.31 vs. the industry median of 2.29, Orion Infusions has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.29, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Infusions's current 5-Year Yield-on-Cost % of 0.69 is 69.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Orion Infusions and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Infusions's current 5-Year Yield-on-Cost % is 0.69, which is 47% below median its own 10-year median of 1.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT315.25, compared to a current price of BDT285.30 — trading 9.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.69, which is 47% below median its 10-year median of 1.31 and 69.9% below the Drug Manufacturers industry median of 2.29. Orion Infusions' overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current 5-Year Yield-on-Cost % is 0.69 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued.
The current stock price of BDT285.30 is trading 9.5% below its estimated GF Value™ of BDT315.25.
GuruFocus considers Orion Infusions to be Modestly Undervalued.
Key valuation signals for DHA:ORIONINFU:
5-Year Yield-on-Cost %: 0.69 (47% below median its 10-year median of 1.31)
GF Value™: BDT315.25 vs. price of BDT285.30 (9.5% below fair value)
Industry Position: 69.9% below the Drug Manufacturers median (#397 of 513)
No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
80GF Score
Get the complete analysis for DHA:ORIONINFU
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONINFU has been successfully added to your 
